our science


Excelimmune is using its proprietary discovery and expression platforms to develop Staphguard® ACT, a novel treatment for Methicillin-resistant Staphylococcus aureus (MRSA) infection. Comprised of fully human antibodies targeting both the bacterium and key bacterial toxins, Staphguard® is designed to affect rapid clearance of the organism itself while neutralizing the toxins responsible for tissue injury and morbidity.

By incorporating several distinct mechanisms of action into one powerful therapeutic, Staphguard® will reduce the outgrowth of resistant organisms through its unique ability to recruit several arms of the immune system and to target a variety of key virulence factors.

Staphguard® represents a safe and effective new class of anti-infective antibody drugs that will provide significant benefit to the patient, reducing the duration of infection, preventing recurrence and lowering the overall cost of treatment.